PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2 | $3 | $5 | $5 |
| Gross Profit | -$2 | -$3 | -$5 | -$5 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $16 | $40 | $53 |
| G&A Expenses | $0 | $14 | $15 | $15 |
| SG&A Expenses | $14 | $14 | $15 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $24 | $27 | $57 | $69 |
| Operating Income | -$25 | -$32 | -$57 | -$73 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $32 | $3 | -$1 |
| Pre-Tax Income | -$25 | $0 | -$54 | -$73 |
| Tax Expense | -$1 | $1 | $0 | $0 |
| Net Income | -$23 | -$0 | -$54 | -$73 |
| % Margin | – | – | – | – |
| EPS | -4.62 | -0.1 | -22.7 | -36.55 |
| % Growth | -4,520% | 99.6% | 37.9% | – |
| EPS Diluted | -4.62 | -0.1 | -22.7 | -36.55 |
| Weighted Avg Shares Out | 5 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 5 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $4 | $0 | $1 |
| Interest Expense | $0 | $1 | $2 | $5 |
| Depreciation & Amortization | $2 | $3 | $5 | $5 |
| EBITDA | -$23 | -$3 | -$48 | -$66 |
| % Margin | – | – | – | – |